A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
The Company We are an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Our commercial products are: (i) ZTlidoÒ (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40M | 57M | - | 38M | - |
| Net Income | -334M | -73M | -114M | -23M | -88M |
| EPS | $-33.63 | $-21.35 | $-44.80 | $-5.95 | $-23.45 |
| Free Cash Flow | 0 | 19M | -21M | -21M | -29M |
| ROIC | -105.8% | -70.9% | -82.2% | -64.5% | -36.3% |
| Gross Margin | - | 70.5% | - | 71.6% | - |
| Debt/Equity | 0.00 | -0.00 | -0.10 | 0.00 | -0.32 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -263M | -83M | -105M | -51M | -36M |
| Operating Margin | -652.4% | -147.4% | - | -133.1% | - |
| ROE | 0.0% | - | - | -64.5% | - |
| Shares Outstanding | 8M | 3M | 3M | 4M | 4M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | 38M | N/A | 57M | 40M |
| Gross Margin | N/A | 71.6% | N/A | 70.5% | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -36M | -51M | -105M | -83M | -263M |
| Op. Margin | N/A | -133.1% | N/A | -147.4% | -652.4% |
| Net Income | -88M | -23M | -114M | -73M | -334M |
| Net Margin | N/A | -61.4% | N/A | -128.7% | -828.6% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -36.3% | -64.5% | -82.2% | -70.9% | -105.8% |
| ROE | N/A | -64.5% | N/A | N/A | 0.0% |
| ROA | -113.5% | -27.0% | -112.9% | -75.0% | -170.1% |
| Cash Flow | |||||
| Op. Cash Flow | -29M | -21M | -21M | 19M | 24M |
| Free Cash Flow | -29M | -21M | -21M | 19M | 0 |
| Owner Earnings | -38M | -30M | -39M | -386K | 4.1M |
| CapEx | 0 | 7K | 30K | 0 | 0 |
| Maint. CapEx | 3.8M | 4.0M | 4.1M | 4.0M | 4.0M |
| Growth CapEx | N/A | 0 | 0 | N/A | 0 |
| D&A | 3.8M | 4.0M | 4.1M | 4.0M | 4.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 5.8M | 5.3M | 15M | 16M | 16M |
| Debt Repayment | 0 | 0 | 5.0M | 64M | 64M |
| Balance Sheet | |||||
| Net Debt | 106M | -2.2M | 13M | -2.4M | -878K |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 878K |
| Long-Term Debt | 72M | 0 | 17M | 845K | 845K |
| Debt/Equity | -0.32 | 0.00 | -0.10 | -0.00 | 0.00 |
| Interest Coverage | -3.0 | -5.3 | -98.7 | -42.5 | -42.5 |
| Equity | -224M | 36M | -173M | -193M | -177M |
| Total Assets | 78M | 87M | 101M | 93M | 197M |
| Total Liabilities | 302M | 50M | 274M | 286M | 456M |
| Intangibles | 52M | 54M | 50M | 46M | 46M |
| Retained Earnings | -353M | -376M | -490M | -563M | -563M |
| Working Capital | -146M | -15M | -204M | -218M | -218M |
| Current Assets | 23M | 30M | 47M | 42M | 42M |
| Current Liabilities | 169M | 45M | 250M | 260M | 260M |
| Per Share Data | |||||
| EPS | -23.45 | -5.95 | -44.80 | -21.35 | -33.63 |
| Owner EPS | -10.15 | -7.77 | -15.46 | -0.11 | 0.54 |
| Book Value | -59.37 | 9.23 | -67.76 | -56.49 | -23.33 |
| Cash Flow/Share | -7.60 | -5.41 | -8.11 | 5.67 | -43.55 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.8M | 3.9M | 2.6M | 3.4M | 7.6M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -0.2 |
| P/FCF | N/A | N/A | N/A | 2.4 | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 13.2 | N/A | N/A | N/A |
| Price/Sales | N/A | 34.4 | N/A | 2.6 | 1.1 |
| FCF Yield | -2.2% | -4.4% | -12.6% | 41.6% | N/A |
| Market Cap | 1.3B | 480M | 164M | 47M | 45M |
| Avg. Price | 348.94 | 333.47 | 184.65 | 43.61 | 5.93 |
| Year-End Price | 351.40 | 122.15 | 64.40 | 13.65 | 5.93 |
Scilex Holding Co passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 1.0x vs a median of 2.4x. The company's 5-year average gross margin is 71.1%. At current prices, the estimated annualized return to fair value is +48.7%.
Scilex Holding Co (SCLX) has a 5-year average return on invested capital (ROIC) of -63.5%. This is below average and may indicate limited pricing power.
Scilex Holding Co (SCLX) has a market capitalization of $45M. It is classified as a small-cap stock.
Scilex Holding Co (SCLX) does not currently pay a regular dividend.
Scilex Holding Co (SCLX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Scilex Holding Co (SCLX) reported annual revenue of $57 million in its most recent fiscal year, based on SEC EDGAR filings.
Scilex Holding Co (SCLX) has a net profit margin of -128.7%. The company is currently unprofitable.
Scilex Holding Co (SCLX) generated $19 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Scilex Holding Co (SCLX) reported earnings per share (EPS) of $-21.35 in its most recent fiscal year.
Scilex Holding Co (SCLX) has a 5-year average gross margin of 71.1%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 4 years of financial data for Scilex Holding Co (SCLX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Scilex Holding Co (SCLX) has a book value per share of $-56.49, based on its most recent annual SEC filing.
No recent press releases.